Cargando…

SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis

SIPRα on macrophages binds with CD47 to resist proengulfment signals, but how the downstream signal of SIPRα controls tumor-infiltrating macrophages (TIMs) is still poorly clarified. Here, we report that the CD47/signal regulatory protein α (SIRPα) axis requires the deneddylation of tyrosine phospha...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yiqing, Zhou, Hui, Liu, Pan, Lv, Dandan, Shi, Yichun, Tang, Bufu, Xu, Jiaqi, Zhong, Tingting, Xu, Wangting, Zhang, Jie, Zhou, Jianying, Ying, Kejing, Zhao, Yongchao, Sun, Yi, Jiang, Zhinong, Cheng, Hongqiang, Zhang, Xue, Ke, Yuehai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927946/
https://www.ncbi.nlm.nih.gov/pubmed/36626230
http://dx.doi.org/10.1172/JCI162870
Descripción
Sumario:SIPRα on macrophages binds with CD47 to resist proengulfment signals, but how the downstream signal of SIPRα controls tumor-infiltrating macrophages (TIMs) is still poorly clarified. Here, we report that the CD47/signal regulatory protein α (SIRPα) axis requires the deneddylation of tyrosine phosphatase SHP2. Mechanistically, Src homology region 2–containing protein tyrosine phosphatase 2 (SHP2) was constitutively neddylated on K358 and K364 sites; thus, its autoinhibited conformation was maintained. In response to CD47-liganded SIRPα, SHP2 was deneddylated by sentrin-specific protease 8 (SENP8), which led to the dephosphorylation of relevant substrates at the phagocytic cup and subsequent inhibition of macrophage phagocytosis. Furthermore, neddylation inactivated myeloid-SHP2 and greatly boosted the efficacy of colorectal cancer (CRC) immunotherapy. Importantly, we observed that supplementation with SHP2 allosteric inhibitors sensitized immune treatment–resistant CRC to immunotherapy. Our results emphasize that the CRC subtype that is unresponsive to immunotherapy relies on SIRPα(hi)SHP2(hi)NEDD8(lo) TIMs and highlight the need to further explore the strategy of SHP2 targeting in CRC therapy.